HK Stock Market Move | InnoCare Pharma (09969) rises over 4%, turns profitable in the first three quarters, with core product orelabrutinib continuing to ramp up sales.

InnoCare Pharma (09969) rose over 4%, up 5.08% as of press time to HK$14.49, with turnover of HK$34.8642 million. On the news front, InnoCare Pharma recently announced its results for the first three quarters of 2026. Total operating revenue was RMB2.099 billion, up 88.21% year on year, of which pharmaceutical sales revenue was RMB1.449 billion, up 41.47% year on year. The growth in operating revenue was mainly due to the continued ramp-up of core product orelabrutinib, new sales contributions from tafasitamab and zurletrectinib, and the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc. Net profit attributable to shareholders of the listed company was approximately RMB656 million, turning profitable from a year-earlier loss. From January to September 2026, net cash flow from operating activities was RMB220 million, turning positive from negative a year earlier, mainly benefiting from increased pharmaceutical sales and licensing revenue, as the company's operating cash flow continued to improve.